Neurocrine Biosciences
Price & Volume
Stats
See more52W Range | $84.23-$160.18 |
Market Cap | $13.1B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $2.8B |
Revenue Growth (YoY) | 28.3% |
Gross Profit (12 Mos) | $1.7B |
Diluted EPS | $4.66 |
News
See moreYahoo Finance • 16 days ago
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum
Yahoo Finance • 2 months ago
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal
Yahoo Finance • 3 months ago
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
Yahoo Finance • 4 months ago
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
About
CEO | Mr. Kyle W. Gano Ph.D. |
Address | 6027 Edgewood Bend Court, San Diego, CA, United States, 92130 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 2,000 |
